Telluride Medical Partners invests in creative opportunities to provide value-added operational and managerial leadership, strategic business planning and the necessary capital to grow prosperous medical device companies. Whether taking the company to full commercialization or an early exit through acquisition, Telluride Medical Partners utilizes its internal team of experts and vast network of service professionals to realize each company's unique business objectives.
Learn more about Telluride Medical Partners' portfolio of companies below.
CAPTURE VASCULAR INC.
The unique design and broad indications for use of the MegaVac Mechanical Thrombectomy System makes it appropriate for several key markets, with a total worldwide market opportunity greater than $500M. Capture’s initial focus is peripheral arterial disease and coronary arterial disease which will address a global market of over 250,000 patients annually.
Workers worldwide are sleep-deprived and are suffering from health problems and lost productivity. With its non-invasive sleep sensing device, Chrona is initially targeting more than 113 million sleep-deprived Americans. The market is expected to experience explosive growth with projections of 248 million devices sold worldwide in 2017 and upwards of one billion in 2020.
LIGHTHILL MEDICAL, INC.
The Society of Interventional Radiology calls Interventional Oncology “the most rapidly changing domain of IR”. Over 700,000 individuals globally are diagnosed with liver cancer alone every year and 85% are non-resectable, which equates to 573,000 individuals who are potential candidates for targeted therapy. This represents a $340M market opportunity.
Utilizing a proprietary open-loop algorithm along with additional sensor inputs across the thoracic cavity, Nespiro has developed a new data-driven solution for mechanical ventilation weaning and prediction of post-extubation complications. As an accessory product business model, Nespiro’s market is an estimated $192M in the U.S. on disposable components alone. However, Nespiro’s technology has a higher value proposition as an integrated product through market share dynamics; a 1% shift in global market share is worth $32M.
NECTERO MEDICAL INC.
Only five percent of patients are candidates for high-risk surgical intervention, which is the only treatment option available today. 600,000+ patients are anxiously living with risk of fatal rupture and greater than two million patients worldwide are living with undiagnosed abdominal aortic aneurysms. Nectero’s low risk, 30 minute vascular procedure, AAvert, is targeting the unmet need of “watchful, waiting and contra-indicated” patients, worth $6B today.
90% of all headaches are tension-related and can usually be traced back to tension in the head, neck and jaw…it’s all connected. Traditional pain medication can provide temporary pain relief but does not address the root of the problem: tension. Relēver is a new device that stretches the muscles in the jaw to help relieve tension and pain in the head, neck and jaw.